Allies promote MRI-guided treatment
Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused
Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused ultrasound, an investigational method of heating and destroying tumors or tissue such as uterine fibroids with millimeter precision. The collaboration will initially focus on preclinical studies leading to future use in the image-guided therapy program at Brigham and Women's Hospital in Boston. Epix and InSightec will share information on their technologies to optimize the use of contrast agents during interventional procedures.
© 2001 Miller Freeman Inc.
3/28/01, Issue # 1506, page 4.